289 related articles for article (PubMed ID: 17239554)
1. [Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].
Brunet-François C; Taieb A; Masquelier B; Le Moing V; Lewden C; Dellamonica P; Cuzin L; Allavena C; Spire B; Chêne G; Raffi F;
Med Mal Infect; 2007 Mar; 37(3):172-7. PubMed ID: 17239554
[TBL] [Abstract][Full Text] [Related]
2. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital.
Smith CJ; Phillips AN; Youle MS; Sabin CA; Lampe FC; Tsintas R; Tyrer M; Johnson MA
HIV Med; 2007 Jan; 8(1):55-63. PubMed ID: 17305933
[TBL] [Abstract][Full Text] [Related]
4. Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.
Bongiovanni M; Bini T; Adorni F; Meraviglia P; Capetti A; Tordato F; Cicconi P; Chiesa E; Cordier L; Cargnel A; Landonio S; Rusconi S; d'Arminio Monforte A
Antivir Ther; 2003 Jun; 8(3):209-14. PubMed ID: 12924537
[TBL] [Abstract][Full Text] [Related]
5. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
Keiser PH; Nassar N
Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
[TBL] [Abstract][Full Text] [Related]
7. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.
Castagna A; Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Hoetelmans R; Nauwelaers D; Lazzarin A
Antivir Ther; 2004 Aug; 9(4):537-43. PubMed ID: 15456085
[TBL] [Abstract][Full Text] [Related]
8. Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results.
Voigt E; Wasmuth JC; Vogel M; Mauss S; Schmutz G; Kaiser R; Rockstroh JK
Infection; 2004 Apr; 32(2):82-8. PubMed ID: 15057572
[TBL] [Abstract][Full Text] [Related]
9. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
10. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
[TBL] [Abstract][Full Text] [Related]
11. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
[TBL] [Abstract][Full Text] [Related]
12. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
[TBL] [Abstract][Full Text] [Related]
13. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
[TBL] [Abstract][Full Text] [Related]
14. Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART.
Bongiovanni M; Chiesa E; Di Biagio A; Meraviglia P; Capetti A; Tordato F; Cicconi P; Biasi P; Bini T; d'Arminio Monforte A
J Antimicrob Chemother; 2005 Jun; 55(6):1003-7. PubMed ID: 15824089
[TBL] [Abstract][Full Text] [Related]
15. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
16. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
Hill A; Marcelin AG; Calvez V
HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad
Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
Kempf DJ; Isaacson JD; King MS; Brun SC; Sylte J; Richards B; Bernstein B; Rode R; Sun E
Antivir Ther; 2002 Sep; 7(3):165-74. PubMed ID: 12487383
[TBL] [Abstract][Full Text] [Related]
19. Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.
King MS; Rode R; Cohen-Codar I; Calvez V; Marcelin AG; Hanna GJ; Kempf DJ
Antimicrob Agents Chemother; 2007 Sep; 51(9):3067-74. PubMed ID: 17576846
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]